Peptide
Tau Peptide
SaveSynthetic peptide fragments derived from or targeting the tau protein, studied in the context of tauopathy immunotherapy and Alzheimer's disease vaccine development.
Quick verdict
Research tool and immunotherapy target. Anti-tau vaccines and antibodies are in clinical development but individual tau peptide fragments are not standalone therapeutics.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Multiple anti-tau immunotherapy trials ongoing (semorinemab, zagotenemab, AADvac1). Tau peptide fragments are used as immunogens, not as direct therapies.
Benefits
- Central target in tauopathy immunotherapy development
- AADvac1 tau-peptide vaccine showed immune response in phase II
Dosage notes
Not applicable as a standalone consumer peptide.
Side effects
- Injection-site reactions with vaccine formulations
- Immune-mediated reactions possible
Who should be cautious
Not a standalone therapeutic. Anti-tau immunotherapy carries immune-related risks.
What this page cannot tell you
Value is as a research and immunotherapy component, not as an injectable peptide for consumers.
Leaderboard scores
- Memory15
Write a review
Sign in to write a review.